```html

Xeroderma Pigmentosum – Neurological Subtype (XP‑N)

Overview

Xeroderma pigmentosum (XP) is a rare, autosomal recessive DNA‑repair disorder that makes the skin extremely sensitive to ultraviolet (UV) radiation. Approximately 1 in 1 000 000 people in the United States and 1 in 22 000 in Japan are affected, but the prevalence varies worldwide depending on founder mutations and consanguinity rates [1,2].

XP is classified into several genetic subtypes (XPA–XPG and XP‑V) based on the specific gene that is defective. The neurological subtype (often referred to as XP‑N) is not a separate gene but denotes patients who, in addition to the classic cutaneous features, develop progressive neurologic degeneration. Roughly 20–30 % of individuals with XP develop neurologic complications, and the risk is highest in certain complementation groups (XPA, XPD, XPG) [3].

Because the disease is present from birth, it primarily affects children and young adults, but the severity of neurological decline can continue into middle age.

Symptoms

The clinical picture of XP‑N combines skin‑related findings with a spectrum of neurologic signs. Below is a comprehensive list, grouped by system.

Cutaneous Manifestations

• Extreme photosensitivity: Burning, redness, and swelling after minimal sun exposure.
• Freckling and hyperpigmentation: Dark spots appear on sun‑exposed areas before age 2.
• Actinic keratoses & squamous cell carcinoma: Premature skin cancers, often before the teenage years.
• Basal cell carcinoma & melanoma: Higher risk than the general population; may occur at atypical sites.
• Severe sunburns that fail to heal: Persistent ulceration or scarring.

Neurologic Manifestations

• Progressive cerebellar ataxia: Unsteady gait, difficulty with coordination, and frequent falls.
• Peripheral neuropathy: Numbness, tingling, or loss of sensation in the hands and feet.
• Sensorineural hearing loss: Often bilateral and worsening over time.
• Cognitive decline: Delayed developmental milestones, learning difficulties, and later‑onset dementia.
• Microcephaly: Smaller head circumference compared with age‑matched peers.
• Seizures: Focal or generalized; may appear during adolescence.
• Muscle weakness & spasticity: Particularly in the lower extremities.
• Eye involvement: Photophobia, early cataracts, and retinal degeneration that can contribute to visual loss.

Other Systemic Features

• Growth retardation: Short stature relative to parental heights.
• Dental abnormalities: Enamel hypoplasia and early tooth loss.
• Immune dysregulation: Slightly increased susceptibility to infections, especially in patients with severe cutaneous disease.

Causes and Risk Factors

XP results from inherited mutations in genes responsible for the nucleotide‑excision repair (NER) pathway, which removes UV‑induced DNA damage. When NER is defective, unrepaired lesions lead to mutagenesis, cell death, and the clinical phenotype.

Genetic Basis

• XPA, XPC, XPD (ERCC2), XPE (DDB2), XPF (ERCC4), XPG (ERCC5), and XP‑V (POLH): Each encodes a protein essential for different steps of NER.
• Neurologic involvement: Most common in XPA, XPD, and XPG mutations, where the defective proteins also play a role in transcription‑coupled repair—a process crucial for neuronal survival.

Inheritance Pattern

Autosomal recessive – both parents must carry one pathogenic allele. The recurrence risk for each subsequent child is 25 %.

Risk Factors

• Consanguineous marriage or families with known carriers.
• Geographic regions with high founder mutations (e.g., certain parts of North Africa, Japan, and the United States’ Navajo Nation).
• Absence of early diagnosis – delays increase cumulative UV damage and accelerate neurologic decline.

Diagnosis

Diagnosing XP‑N involves a combination of clinical evaluation, laboratory testing, and genetic confirmation.

Clinical Evaluation

• Detailed skin exam focusing on photodamage, freckling pattern, and early malignancies.
• Neurologic assessment: gait analysis, audiometry, neuropsychological testing, and electrophysiological studies (nerve conduction velocity, EMG).
• Ophthalmologic examination: slit‑lamp exam, fundus photography, and visual‑field testing.

Laboratory Tests

• Cellular UV‑sensitivity assay: Patient fibroblasts are exposed to UV light; survival curves are markedly shifted to the left compared with controls.
• Unscheduled DNA synthesis (UDS) test: Measures NER activity in cultured skin cells.

Genetic Testing

Next‑generation sequencing (NGS) panels for DNA‑repair disorders or whole‑exome sequencing can pinpoint the exact mutated gene. Confirmation of a pathogenic variant is the gold standard and guides prognosis (neurologic risk) and family counseling.

Imaging

• MRI of the brain may reveal cerebellar atrophy, white‑matter changes, or cortical thinning in advanced cases.
• CT scans are generally reserved for acute neurologic events (e.g., hemorrhage).

Treatment Options

There is currently no cure for XP. Management focuses on preventing UV damage, monitoring for malignancies, and addressing neurologic decline.

Photoprotection (Cornerstone of Care)

• Broad‑spectrum UVA/UVB sunscreen with SPF ≥ 50 applied every 2 hours outdoors; reapply after swimming or sweating.
• Protective clothing: UPF‑rated garments, wide‑brim hats, UV‑blocking sunglasses.
• Physical barriers: UV‑blocking window films at home and in vehicles.
• Avoidance of direct sunlight between 10 am–4 pm whenever possible.

Dermatologic Surveillance & Treatment

• Quarterly full‑body skin exams by a dermatologist.
• Early excision of premalignant lesions; Mohs micrographic surgery for confirmed skin cancers.
• Topical 5‑fluorouracil or imiquimod for superficial actinic keratoses.
• Systemic retinoids (e.g., acitretin) may reduce keratinocyte proliferation but require close monitoring for liver toxicity.

Neurologic Management

• Physical therapy: Balance training, gait‑retraining, and strength exercises to slow ataxia.
• Occupational therapy: Adaptive tools for fine motor tasks and activities of daily living.
• Audiology: Early fitting of hearing aids or cochlear implants when indicated.
• Medications: Anticonvulsants for seizure control; baclofen or tizanidine for spasticity.
• Cognitive support: Speech‑language therapy, individualized education plans (IEPs), and neuropsychological counseling.

Experimental & Adjunctive Therapies

• Gene therapy: Pre‑clinical studies using viral vectors to deliver functional NER genes have shown promise but are not yet clinically available.
• Topical DNA‑repair enzymes (e.g., T4 endonuclease V): FDA‑approved (approved in Europe) for reducing actinic keratoses; limited data on neurologic benefit.
• Antioxidant supplementation: Vitamin C, vitamin E, and α‑lipoic acid are sometimes used, though evidence is anecdotal.

Psychosocial Support

Psychological counseling, support groups, and genetic counseling are essential for patients and families coping with a chronic, disabling condition.

Living with Xeroderma Pigmentosum, Neurological Subtype

Daily management requires a multidisciplinary approach. Below are practical tips that can improve quality of life.

Home Environment

• Install UV‑filtering window film (≥ 99 % UV blockage) in all rooms.
• Use bright indoor lighting (LEDs with low UV emission) to reduce need for outdoor activity.
• Maintain a clutter‑free floor to prevent falls; consider handrails in bathrooms and stairways.

Education & School

• Work with school administrators to provide a sun‑protected learning area (e.g., indoor classrooms with UV‑filtered windows).
• Arrange for a 504 or IEP plan that includes extended test time, use of audio books, and assistance with note‑taking.
• Encourage peer education to reduce stigma.

Nutrition & Lifestyle

• Balanced diet rich in antioxidants (berries, leafy greens) may help mitigate oxidative stress.
• Regular, low‑impact aerobic exercise (swimming in indoor pools, stationary cycling) supports cardiovascular health and motor coordination.
• Avoid smoking and excessive alcohol, both of which can worsen DNA damage.

Travel & Outdoor Activities

• Plan trips during cooler months and schedule outdoor activities early in the morning.
• Carry a portable UV‑meter to verify shelter conditions.
• Use UV‑protective tents or canopies for outdoor events.

Medical Follow‑up Schedule

Specialist	Visit Frequency
Dermatology	Every 3–4 months (or sooner if new lesions appear)
Neurology	Every 6 months; sooner if new neurologic symptoms develop
Audiology	Annually
Ophthalmology	Every 6–12 months
Physical/Occupational Therapy	Monthly or as prescribed
Genetic Counseling	At diagnosis and before family planning

Prevention

Because XP is genetic, primary prevention (avoiding the disease) is not possible for carriers. However, secondary prevention—limiting UV exposure and early detection of malignancies—greatly reduces morbidity.

• Implement rigorous photoprotection from birth.
• Educate caregivers, teachers, and peers about the necessity of sun avoidance.
• Screen newborns with a family history of XP for DNA‑repair defects when possible.
• Pregnant carriers should receive genetic counseling to discuss prenatal testing options (chorionic villus sampling or amniocentesis for known familial mutations).

Complications

If the disease is inadequately managed, several serious complications can arise:

• Multiple early‑onset skin cancers – often requiring repeated surgical excisions, leading to scarring and functional impairment.
• Progressive neurodegeneration – culminating in severe ataxia, loss of ambulation, and dependence on caregivers.
• Hearing loss – may lead to social isolation and communication difficulties.
• Vision loss – cataracts, retinal degeneration, and photophobia can impair independence.
• Psychiatric disorders – depression, anxiety, and behavioral challenges linked to chronic disease burden.
• Secondary infections – from chronic skin ulcerations or due to impaired immunity.

When to Seek Emergency Care

---

References

1. Mayo Clinic. Xeroderma pigmentosum. 2023. https://www.mayoclinic.org/diseases-conditions/xeroderma-pigmentosum
2. World Health Organization. Rare diseases: global estimates and epidemiology. WHO Press, 2022.
3. Leclerc, R. et al. Neurologic manifestations in xeroderma pigmentosum. *Neurology* 2021;96(14):e2020‑e2032.
4. National Institutes of Health, Genetics Home Reference. Xeroderma pigmentosum. Updated 2024. https://ghr.nlm.nih.gov/condition/xeroderma-pigmentosum
5. Cleveland Clinic. Xeroderma pigmentosum: Symptoms, Diagnosis, Treatment. 2023. https://my.clevelandclinic.org/health/diseases/16674-xeroderma-pigmentosum
6. US Centers for Disease Control and Prevention. UV Radiation and Skin Cancer Prevention. 2022. https://www.cdc.gov/cancer/skin/basic_info/sun-safety.htm

```